ArticleCaspian journal of internal medicine2019
The role of Interleukin-10 and 13 in tuberculosis-associated pulmonary dysfunction.
Article in Caspian journal of internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Activation of the Nuclear Factor Kappa-light-chain-enhancer of Activated B-cells Pathway Induces a Pro-inflammatory Network in Patients with Pulmonary Tuberculosis.Annals of African medicine · 2026Article
- Serosal membrane tuberculosis in Iran: A comprehensive review of evidences.Journal of clinical tuberculosis and other mycobacterial diseases · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary dysfunctions are frequently encountered after tuberculosis treatment in clinical practice. In the present study, the role of interleukin-10 and 13 in a tuberculosis-associated pulmonary dysfunction was investigated.
methodsThis is a semi-experimental study on 40 patients selected from referral tuberculosis care center in Birjand, Iran, during 2015-2017. The cases with major medical disorders including those with underlying lung disease were excluded from the study. Informed consent was prepared from each patient, and then blood sample was obtained, serum was extracted and refrigerated at -70 C° at the start (time 1), 2 months (time 2) and 6 months (time 3) after onset of treatment for tuberculosis. Spirometry was also performed at time 2. Finally, 24 patients completed the study.
resultsOf the 24 patients with the mean age of 60.87±21.50 years in the study, 9 (37%) were males and 15 (62.5%) were females. Abnormal spirometry was observed in 20 (83.3%) subjects at time 2, of whom 12 (60%) were restrictive and 8 (40%) obstructive. The mean changes of interleukin 10 from the start to end of the treatment were 89.00±89.47 (P=1.00), -29.36±40.21 (P=0.02) and 3.70±29.98 (P=0.1) in patients with normal, obstructive and restrictive spirometery, respectively (normal vs obstructive and restrictive; p<0.01). While in interleukin 10, changes for interleukin-13 were 77.90±145.97, 6.35±133.10 and -13.35±46.66 (P=0.4), respectively.
conclusionUpregulation of IL-10 during tuberculosis treatment might be considered as a protective factor against lung dysfunction. In patients with obstructive form, there was a marked decrease in interleukin-10.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.